Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients

Cancer Science

Volumn 103, Issue 3, 2012, Pages 587-592

  Mukasa, Akitake ^a   Takayanagi, Shunsaku ^a   Saito, Kuniaki ^a   Shibahara, Junji ^a   Tabei, Yusuke ^b   Furuya, Kazuhide ^c   Ide, Takafumi ^d   Narita, Yoshitaka ^e   Nishikawa, Ryo ^f   Ueki, Keisuke ^g   Saito, Nobuhito ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; CHILD; CHROMOSOME 1P; CHROMOSOME 9Q; CHROMOSOME DELETION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; JAPANESE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; ASIAN; BRAIN TUMOR; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84859712831     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02175.x     Document Type: Article

References (36)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System, 4th edn. Lyon: International Agency for Research on Cancer, 2007.
2. Parsons DW, Jones S, Zhang X et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science 2008; 321: 1807-12.
3. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol (Berl) 2008; 116: 597-602.
4. Ichimura K, Pearson DM, Kocialkowski S et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009; 11: 341-7.
5. Sonoda Y, Kumabe T, Nakamura T et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 2009; 100: 1996-8.
6. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas. Am J Pathol 2009; 174: 1149-53.
7. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73.
8. Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-66.
9. Ward PS, Patel J, Wise DR et al. The Common Feature of Leukemia- Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting a-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell 2010; 17: 225-34.
10. Bleeker FE, Lamba S, Leenstra S et al. IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009; 30: 7-11.
11. Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44.
12. Xu W, Yang H, Liu Y et al. Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of a-Ketoglutarate-Dependent Dioxygenases. Cancer Cell 2011; 19: 17-30.
13. Lesniak M, Jin G, Reitman ZJ et al. 2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+- Dependent Isocitrate Dehydrogenase Mutations. PLoS ONE 2011; 6: e16812.
14. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clin Cancer Res 2009; 15: 6002-7.
15. Sanson M, Marie Y, Paris S et al. Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. J Clin Oncol 2009; 27: 4150-4.
16. Van den Bent MJ, Dubbink HJ, Marie Y et al. IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: a Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16: 1597-604.
17. Shibahara I, Sonoda Y, Kanamori M et al. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 2011; DOI: 10.1007/s10147-011-0323-2 [Epub ahead of print].
18. Dubbink HJ, Taal W, Van Marion R et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009; 73: 1792-5.
19. Houillier C, Wang X, Kaloshi G et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75: 1560-6.
20. Kim Y-H, Nobusawa S, Mittelbronn M et al. Molecular Classification of Low-Grade Diffuse Gliomas. Am J Pathol 2010; 177: 2708-14.
21. Jha P, Suri V, Sharma V et al. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol 2011; 91: 385-93.
22. Qi SA, Yu L, Lu YT et al. IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep 2011; 26: 1479-85.
23. Ueki K, Nishikawa R, Nakazato Y et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002; 8: 196-201.
24. Mukasa A, Ueki K, Matsumoto S et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002; 21: 3961-8.
25. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59: 793-7.
26. Labussiere M, Idbaih A, Wang XW et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010; 74: 1886-90.
27. Korshunov A, Meyer J, Capper D et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009; 118: 401-5.
28. Horbinski C, Kofler J, Yeaney G et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol 2011; 21: 564-74.
29. Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell 2010; 18: 553-67.
30. Christensen BC, Smith AA, Zheng S et al. DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma. J Natl Cancer Inst 2010; 103: 143-53.
31. Laffaire J, Everhard S, Idbaih A et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 2010; 13: 84-98.
32. Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell 2010; 17: 510-22.
33. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
34. Rivera AL, Pelloski CE, Gilbert MR et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 2010; 12: 116-21.
35. Van den Bent MJ, Dubbink HJ, Sanson M et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009; 27: 5881-6.
36. Hartmann C, Hentschel B, Wick W et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (Berl) 2010; 120: 707-18.